ATX MS 1467

Drug Profile

ATX MS 1467

Alternative Names: Antigen processing-independent epitopes - Apitope Technology; API 1,4,6,7; ATX-MS-01; ATX-MS-1467; M-2736; MSC2358825A

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apitope Technology
  • Class Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; MHC class II gene modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 21 Feb 2017 Efficacy and adverse event data from a phase IIa trial in Multiple sclerosis released by Apitope Technology
  • 21 Feb 2017 Apitope Technology plans a phase IIb trial for Multiple sclerosis
  • 19 Oct 2016 ATX MS 1467 is available for licensing as of 17 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top